Partnerships
Scarless Laboratories is a clinical-stage biotechnology company focused on revolutionizing tissue repair and transforming the billion-dollar scar prevention, scar reduction, and chronic wound healing industries. Founded by UCLA Professors Drs. Chia Soo, Kang Ting, and Zhong Zheng, Scarless is based in Los Angeles, California, and supported by private investors and the National Institutes of Health (NIH).
LinkingPros is a healthcare development network that connects pharmaceutical, biotechnology, and medical technology companies with experienced experts across strategy, regulatory affairs, clinical development, CMC, compliance, and project management. Through its global professional network, LinkingPros helps partners streamline medical product development and accelerate the path from concept to market approval.
Saint Therapeutics conducts R&D in collaboration with Scarless Laboratories and partners with Academia Sinica’s National Biotechnology Research Park (NBRP) in Taipei. The NBRP serves as Taiwan’s premier ecosystem for biomedical research, linking industry, academia, and government.
“State of the Art” Research and Development Laboratories was housed in the prestigious Magnify CNSI Facility on the campus of the University of California at Los Angeles. These facilities have provided a means for research on the SLI-F06 platform technologies to be developed and marketed by Saint Therapeutics.
(Through Scarless Laboratories)
Basic research for SLI-F06 has been generously supported by the National Institute of Health (NIH) through their SBIR and commercialization readiness programs(CRP).
(Through Scarless Laboratories)
Saint Therapeutics also operates through BioLabs Los Angeles (BioLabs LA) at the Lundquist Institute — a state-of-the-art 18,000-square-foot biotechnology incubator within an 80,000-square-foot research facility, supporting innovation and collaboration in the Los Angeles biotech community.
The Dana Dunn Group is an invaluable partner for Saint Therapeutics, offering extensive regulatory expertise and a strong track record in the biopharmaceutical sector. Led by Dana Dunn, an international regulatory expert with over 30 years of consulting experience, the group specializes in developing strategic regulatory plans and navigating complex FDA processes. Together, they ensure compliance and facilitate successful regulatory pathways for innovative therapies, enhancing Saint Therapeutics’ potential for success in the market.
